The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation

Liver Transplantation

Volumn 14, Issue 9, 2008, Pages 1287-1293

  Hanouneh, Ibrahim A ^a   Feldstein, Ariel E ^a   McCullough, Arthur J ^a   Miller, Charles ^a   Aucejo, Federico ^a   Yerian, Lisa ^a   Lopez, Rocio ^a   Zein, Nizar N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TREATMENT FAILURE; VIRUS CULTURE; VIRUS LOAD;

ADULT; AGED; BIOPSY; DISEASE PROGRESSION; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 51349121640     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21524     Document Type: Article

References (28)

1. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002:122:889-896.
3. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
4. Saab S, Shpaner A, Zhao Y, Brito I, Durazo F, Han S, et al. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant 2006;6:1890-1895.
5. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-1219.
6. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-S56.
7. Foxton MR, Quaglia A, Muiesan P, Heneghan MA, Portmann B, Norris S, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006;6:1922-1929.
8. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848.
9. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005;100:1509-1515.
10. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-597.
11. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36:729-736.
12. Romero-Gomez M. Hepatitis C and insulin resistance: steatosis, fibrosis and non-response. Rev Esp Enferm Dig 2006;98:605-615.
13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
14. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995;311:1401-1405.
15. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-419.
16. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Path 1995;19:1409-1417.
17. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995;60:1057-1060.
18. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
19. Biggins SW, Terrault NA. Should HCV-related cirrhosis be a contraindication for retransplantation? Liver Transpl 2003;9:236-238.
20. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-906.
21. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000;69:781-789.
22. Navasa M, Bustamante J, Marroni C, Gonzalez E, Andreu H, Esmatjes E, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 1996;25:64-71.
23. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13:1078-1079.
24. Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007; 83:1141-1150.
25. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005;48:1684-1699.
26. Hanley AJ, Karter AJ, Williams K, Festa A, D'Agostino RB Jr, Wagenknecht LE, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005;112:3713-3721.
27. Karter AJ, D'Agostino RB Jr, Mayer-Davis EJ, Wagenknecht LE, Hanley AJ, Hamman RF, et al. Abdominal obesity predicts declining insulin sensitivity in non-obese normoglycaemics: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Obes Metab 2005;7:230-238.
28. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995;311:158-161.